Company Overview - TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease using RNA therapeutics [3] - The company utilizes its proprietary TTX nanoparticle platform for the intelligent design and effective delivery of RNA therapeutics [3] - The lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [3] - TransCode has a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for various cancers [3] Special Meeting Outcomes - The Special Meeting held on February 25, 2025, resulted in the approval of two proposals by a majority of votes cast [5] - Proposal One involved the approval of the full issuance of shares of Common Stock upon the exercise of Series C and Series D Warrants, adjustments to the exercise price, and an alternative cashless exercise feature [5] - Proposal Two allowed for the adjournment of the Special Meeting to solicit further votes if necessary, which was also approved by a majority [5]
TransCode Therapeutics, Inc. Announces Results of Special Meeting